Please login to the form below

Not currently logged in
Email:
Password:

David Noble to leave Edelman

David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure

David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure.

Noble has been heading the agency's specialist medical communications business unit for more than three years. He is to leave this month following a three-week consultation process.

Steve Spurr who leads Edleman's ethical healthcare division will take over Noble's responsibilities.

Robert Phillips, Edelman UK CEO told PR Week: "The BioScience and Rx divisions will remain separate, but will be headed by Steve. We are reorganising internally to have more fluent interaction between the teams."

The BioScience division specialises in advisory board management, clinical trial recruitment/retention, market access support, publication planning, meetings and symposia.

13th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...